<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30274" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Torsade de Pointes</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cohagan</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>Temple University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brandis</surname>
            <given-names>Dov</given-names>
          </name>
          <aff>Temple University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Cohagan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dov Brandis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30274.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Torsades de Pointes is a type of polymorphic ventricular tachycardia characterized on electrocardiogram by oscillatory changes in amplitude of the QRS complexes around the isoelectric line. Torsades de Pointes is associated with QTc prolongation, which is the heart rate adjusted lengthening of the QT interval. The rhythm may terminate spontaneously or may degenerate into ventricular fibrillation. This activity reviews the evaluation and management of Torsades de Pointes and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain risk factors for developing Torsades de Pointes.</p></list-item><list-item><p>Identify Torsades de Pointes on an electrocardiogram.</p></list-item><list-item><p>Explain how to manage Torsades de Pointes.</p></list-item><list-item><p>Explain the importance of improving coordination amongst the interprofessional team to enhance the delivery of care for patients affected by Torsades de Pointes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30274&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30274">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30274.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Torsades de Pointes is a type of&#x000a0;polymorphic ventricular tachycardia characterized by a gradual change in amplitude and twisting of the QRS complexes around an isoelectric line on the electrocardiogram. Torsades de Pointes&#x000a0;is associated with QTc prolongation, which is the heart rate adjusted lengthening of the QT interval. A QTc is considered long when it is greater than 450 ms in males and 460 ms in females. A QTc greater than 500 ms has been associated with a two-fold to three-fold increase in risk for Torsades de Pointes. The rhythm may terminate spontaneously or may degenerate into ventricular fibrillation.<xref ref-type="bibr" rid="article-30274.r1">[1]</xref><xref ref-type="bibr" rid="article-30274.r2">[2]</xref><xref ref-type="bibr" rid="article-30274.r3">[3]</xref></p>
      </sec>
      <sec id="article-30274.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Torsades de pointes is the result of QTc prolongation which can either be congenital or acquired. Acquired QTc prolongation is most often drug-related. There is an extensive list of medications that can predispose a person to torsades. The list includes but is not limited to: antiarrhythmics, antipsychotics, antiemetics, antifungals, and antimicrobials. Substances that slow the hepatic metabolism of these medications can potentiate QTc prolongation leading to an increased likelihood of torsades de pointes. Congenital prolonged QT has two genetic variants: Jervell and Lange-Nielsen and Romano-Ward syndrome. The former is associated with congenital deafness. Prolonged QTc and Torsades are also associated with certain risk factors that include: older age (older than 65), female gender, hypokalemia, hypocalcemia, hypomagnesemia, bradycardia, heart disease, and diuretic use.<xref ref-type="bibr" rid="article-30274.r4">[4]</xref><xref ref-type="bibr" rid="article-30274.r5">[5]</xref></p>
        <p>Two rare congenital long QT syndromes include Romano-Ward syndrome and Jervell and Lange Nielsen syndrome.</p>
      </sec>
      <sec id="article-30274.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of congenital prolonged QT is largely&#x000a0;unknown. Figures estimate between 1:2000 and 1:20,000 have the genetic mutation for QT prolongation. Clinically more males than females exhibit the trait. Little is also known about the prevalence or incidence of drug-induced torsades de pointes.&#x000a0;This is mainly because the arrhythmia is often transient, and an accurate diagnosis requires an ECG to be recorded during the event. Several European centers estimate that the annual reporting rate of drug-induced Torsades de Pointes&#x000a0;is between 0.8 and 1.2 per million person-years. The incidence of drug-induced Torsades de Pointes&#x000a0;also varies based on the drug in question and the population being studied.<xref ref-type="bibr" rid="article-30274.r6">[6]</xref><xref ref-type="bibr" rid="article-30274.r7">[7]</xref><xref ref-type="bibr" rid="article-30274.r8">[8]</xref></p>
      </sec>
      <sec id="article-30274.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The proposed mechanism for Torsades de Pointes involves inhibition of the delayed rectifier potassium current. This leads to an excess of positive ions within the cellular membrane causing a prolonged repolarization phase. If an ectopic beat is generated during this prolonged repolarization phase, known as an R on T phenomenon, this can result in Torsades de Pointes. Both congenital and drug-induced QT prolongation affect the cellular membrane in similar fashions by blocking the potassium channel. Torsades de Pointes&#x000a0;is slightly different from ventricular fibrillation in that it can spontaneously resolve. However, Torsades de Pointes&#x000a0;can ultimately progress into venticular fibrillation if left untreated.<xref ref-type="bibr" rid="article-30274.r9">[9]</xref></p>
      </sec>
      <sec id="article-30274.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Around 50% of patients with Torsades de Pointes are asymptomatic. The most common symptoms reported are syncope, palpitations, and dizziness. However, cardiac death is the presenting symptom in up to 10% of patients.</p>
        <p>Patients with Jervell and Lange Nielsen syndrome may have a history of deafness.</p>
        <p>Today one needs to be aware that drug-induced&#x000a0;long QT syndrome is common and hence, a thorough medication history must&#x000a0;be obtained.</p>
        <p>Patients with torsade may be hypotensive, have a rapid pulse and have loss of consciousness.</p>
      </sec>
      <sec id="article-30274.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>An electrocardiogram is paramount in the diagnosis of Torsades de Pointes. The characteristic finding is a twisting of the QRS complexes around an isoelectric line. Torsades de Pointes&#x000a0;is triggered by a PVC occurring on a preceding T wave. The onset of Torsades de Pointes&#x000a0;is often preceded by a run of short-long-short R-R intervals. A QT nomogram can provide a sensitive and specific assessment of the risk of Torsades de Pointes&#x000a0;in drug-induced QTc prolongation. Any value plotted above the line on the nomogram puts the patient at risk of Torsades de Pointes.<xref ref-type="bibr" rid="article-30274.r10">[10]</xref><xref ref-type="bibr" rid="article-30274.r11">[11]</xref></p>
      </sec>
      <sec id="article-30274.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The first step in managing Torsades de Pointes&#x000a0;is preventing its onset by targeting modifiable risk factors. This includes discontinuing any QT prolonging drugs and optimizing a patient&#x02019;s electrolyte profile. Correcting hypokalemia, hypomagnesemia, and hypocalcemia can all help to prevent the onset of torsades. There are a small number of studies that show a possible&#x000a0;prophylactic benefit of oral or IV magnesium for those patients with drug-induced prolonged QT. However, the overall benefit is not well established, and there is little evidence that magnesium has any effect on the actual QT interval. The management of Torsades de Pointes&#x000a0;begins with assessing if the patient is hemodynamically stable. Most episodes of torsades are self-limiting. However, the danger lies in those patients who go on to&#x000a0;develop ventricular fibrillation. For those patients with hypotension or in cardiac arrest from Torsades de Pointes, electrical cardioversion should be performed. Synchronized cardioversion should be performed on a hemodynamically unstable patient in torsades who has a pulse, (100J monophasic, 50J Biphasic). Pulseless torsades should be defibrillated. Intravenous magnesium is the first-line pharmacologic therapy in Torsades de Pointes. Magnesium has been shown to stabilize the cardiac membrane, though the exact mechanism is unknown. The recommended initial dose of magnesium is a slow 2 g IV push. An infusion of 1 gm to 4 gm/hr should be started to keep the magnesium levels greater than 2 mmol/L. Once the magnesium level is greater than 3 mmol/L, the infusion can be stopped. Severe magnesium toxicity is seen with levels greater than 3.5 mmol/L and can present as confusion, respiratory depression, coma, and cardiac arrest. It is important to remember to correct any hypokalemia&#x000a0;as well. Serum potassium should be maintained between 4.5&#x000a0;mmol/L&#x000a0;and 5 mmol/L when treating Torsades de Pointes.</p>
        <p>For a patient that continues to have intermittent runs of Torsades de Pointes, despite treatment with magnesium, increasing the heart rate may also help. This can be done pharmacologically with medications such as isoproterenol. Isoproterenol has been shown to help prevent Torsades de Pointes&#x000a0;in patients with prolonged QT that is&#x000a0;refractory to magnesium. It is a non-selective beta agonist, which increases the heart rate and shortens the QT interval. This lowers the likelihood of an R-on-T phenomenon that can lead to TdP. Isoproterenol can be given as an IV push of 10 mcg to 20mcg or an infusion titrated to maintain a heart rate of 100 bpm. Isoproterenol is, however, contraindicated in patients with congenital prolonged QT, because it can paradoxically lengthen the QT interval. A final option for terminating torsades is overdrive pacing. There are limited studies on the success of pacing for treatment of Torsades de Pointes; however, there&#x000a0;are numerous case reports that show it is a viable option. Overdrive pacing can be used in the setting of both frequent runs of torsades and Torsades de Pointes&#x000a0;that is refractory to magnesium. The rate must be set to overcome the patient&#x02019;s intrinsic rate of ectopy. Ventricular rates of 90&#x000a0;bpm&#x000a0;to 110 bpm are usually sufficient to overcome the arrhythmia, however occasionally rates up to 140&#x000a0;bpm&#x000a0;have been required for some patients. Overdrive pacing is recommended for both drug and chemical induced Torsades de Pointes.<xref ref-type="bibr" rid="article-30274.r12">[12]</xref><xref ref-type="bibr" rid="article-30274.r7">[7]</xref><xref ref-type="bibr" rid="article-30274.r13">[13]</xref></p>
      </sec>
      <sec id="article-30274.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Ventricular tachycardia/fibrillation</p>
          </list-item>
          <list-item>
            <p>Dialysis-related complications</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Drug toxicity- antihistamines, antiarrhythmics</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30274.s10" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Ventricular fibrillation</p>
          </list-item>
          <list-item>
            <p>Sudden cardiac death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30274.s11" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Electrophysiologist</p>
          </list-item>
          <list-item>
            <p>Cardiologist</p>
          </list-item>
          <list-item>
            <p>Geneticist if the patient has congenital long QT syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30274.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Torsade is a rare arrhythmia, but it can quickly be fatal if not diagnosed and treated. Patients may present with a range of symptoms but it is the ECG that is diagnostic. While the arrhythmia&#x000a0;is managed&#x000a0;by physicians, all nurses should recognize this arrhythmia and consult with the cardiologist. Those who have a congenital&#x000a0;disorder&#x000a0;causing&#x000a0;prolonged&#x000a0;QT&#x000a0;interval should be told to refrain from exercise. The pharmacist should educate the patient on medication compliance to prevent recurrence. Close&#x000a0;follow up is required because the risk of sudden death is present. The pharmacist must be aware of all drugs the patient is taking and ensure that he or she is not on any medications that prolonged the QT interval. Finally, the nurse should teach all patients how to monitor their pulses and note for the presence of&#x000a0;any adverse effects from the medications. In addition, the family should be taught&#x000a0;basic life support. <xref ref-type="bibr" rid="article-30274.r14">[14]</xref><xref ref-type="bibr" rid="article-30274.r15">[15]</xref><xref ref-type="bibr" rid="article-30274.r16">[16]</xref>(Level V)&#x000a0;</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>For patients with congenital long QT syndromes, the mortality for untreated patients is more than 50% over 5 years. With intervention, the mortality rates can be decreased to single digits. In patients with acquired long QT syndrome, the prognosis is good as long as the trigger medication or factor has been identified and discontinued. <xref ref-type="bibr" rid="article-30274.r17">[17]</xref><xref ref-type="bibr" rid="article-30274.r18">[18]</xref>(Level V)</p>
      </sec>
      <sec id="article-30274.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30274&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30274">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/torsade-de-pointes/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30274">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30274/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30274">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30274.s14">
        <fig id="article-30274.image.f1" position="float" orientation="portrait">
          <caption>
            <p>torsade de pointes Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Torsade" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30274.s15">
        <fig id="article-30274.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Torsade de pointes Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="torsade-1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30274.s16">
        <fig id="article-30274.image.f3" position="float" orientation="portrait">
          <caption>
            <p>This is a classic 12 lead EKG of a patient with Torsade de Pointes. It shows the polymorphic nature of the tachycardia, the long QT interval and the initiation of the tachycardia with a late coupled P.V.C. Contributed by Michael Rosengarten BEng, MD.McGill (CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/deed.en)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="112_xCardioNetworks_ECGpediax" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30274.s17">
        <title>References</title>
        <ref id="article-30274.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Laecke</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hypomagnesemia and hypermagnesemia.</article-title>
            <source>Acta Clin Belg</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-47</page-range>
            <pub-id pub-id-type="pmid">30220246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Verkerk</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Long QT Syndrome and Sinus Bradycardia-A Mini Review.</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>106</fpage>
            <pub-id pub-id-type="pmid">30123799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.</article-title>
            <source>Postgrad Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>130</volume>
            <issue>8</issue>
            <fpage>660</fpage>
            <page-range>660-665</page-range>
            <pub-id pub-id-type="pmid">30145917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Vecchis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ariano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Biase</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Noutsias</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acquired drug-induced long QTc: new insights coming from a retrospective study.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>1645</fpage>
            <page-range>1645-1651</page-range>
            <pub-id pub-id-type="pmid">30112668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salem</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dureau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bachelot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Germain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voiriot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lebourgeois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tr&#x000e9;gou&#x000eb;t</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hulot</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Funck-Brentano</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.</article-title>
            <source>JAMA Cardiol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>3</volume>
            <issue>9</issue>
            <fpage>877</fpage>
            <page-range>877-882</page-range>
            <pub-id pub-id-type="pmid">30073300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reichlin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fasel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leuppi-Taegtmeyer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports.</article-title>
            <source>Glob Cardiol Sci Pract</source>
            <year>2017</year>
            <month>Jun</month>
            <day>30</day>
            <volume>2017</volume>
            <issue>2</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">29644223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porta-S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spears</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nanthakumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thavendiranathan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2017</year>
            <month>Dec</month>
            <day>07</day>
            <volume>6</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">29217664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heemskerk</surname>
                <given-names>CPM</given-names>
              </name>
              <name>
                <surname>Pereboom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Stralen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>van den Bemt</surname>
                <given-names>PMLA</given-names>
              </name>
              <name>
                <surname>Kuijper</surname>
                <given-names>AFM</given-names>
              </name>
              <name>
                <surname>van der Hoeven</surname>
                <given-names>RTM</given-names>
              </name>
              <name>
                <surname>Mantel-Teeuwisse</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for QTc interval prolongation.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-191</page-range>
            <pub-id pub-id-type="pmid">29167918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldzizhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manuylova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marchenko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kryvalap</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Ventricular Tachycardias: Characteristics and Management.</article-title>
            <source>Crit Care Nurs Clin North Am</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-29</page-range>
            <pub-id pub-id-type="pmid">27484660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Groffen</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bikker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christiaans</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Long QT Syndrome Overview</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>2</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">20301308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mantovani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gintant</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kowey</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Klotzbaugh</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sager</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Stockbridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Strnadova</surname>
                <given-names>C</given-names>
              </name>
              <collab>Cardiac Safety Research Consortium</collab>
            </person-group>
            <article-title>Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>997</fpage>
            <page-range>997-1012</page-range>
            <pub-id pub-id-type="pmid">29672845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Lemos</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kletas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Badry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>198</fpage>
            <page-range>198-204</page-range>
            <pub-id pub-id-type="pmid">29298624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Callans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dickfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Matlock</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Myerburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Heart Rhythm</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e190</fpage>
            <page-range>e190-e252</page-range>
            <pub-id pub-id-type="pmid">29097320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crimmins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vashit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Harman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A multidisciplinary approach to prenatal treatment of congenital long QT syndrome.</article-title>
            <source>J Clin Ultrasound</source>
            <year>2017</year>
            <month>Mar</month>
            <day>04</day>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-170</page-range>
            <pub-id pub-id-type="pmid">27492745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shulman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Misher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tentler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>489</fpage>
            <page-range>489-501</page-range>
            <pub-id pub-id-type="pmid">25382979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Aerde</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kalverdijk</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Reimer</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Widdershoven</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>[QT interval prolongation and psychotropic drugs in children and adolescents: proposed guideline].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2008</year>
            <month>Aug</month>
            <day>09</day>
            <volume>152</volume>
            <issue>32</issue>
            <fpage>1765</fpage>
            <page-range>1765-70</page-range>
            <pub-id pub-id-type="pmid">18754307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tse</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Bazoukis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MTV</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>MCS</given-names>
              </name>
              <name>
                <surname>Letsas</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Baranchuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>GX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>WKK</given-names>
              </name>
            </person-group>
            <article-title>Predictive Value of T <sub><bold>peak</bold></sub> - T <sub><bold>end</bold></sub> Indices for Adverse Outcomes in Acquired QT Prolongation: A Meta-Analysis.</article-title>
            <source>Front Physiol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1226</fpage>
            <pub-id pub-id-type="pmid">30233403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30274.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramalho</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes.</article-title>
            <source>Rev Port Cardiol (Engl Ed)</source>
            <year>2018</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>435</fpage>
            <page-range>435-446</page-range>
            <pub-id pub-id-type="pmid">29636202</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
